Halozyme Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Halozyme Therapeutics wird ein jährliches Gewinn- und Umsatzwachstum von 21.7% bzw. 15% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 23.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 84.2% betragen.

Wichtige Informationen

21.7%

Wachstumsrate der Gewinne

23.1%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	31.4%
Wachstumsrate der Einnahmen	15.0%
Zukünftige Eigenkapitalrendite	84.2%
Analystenabdeckung	Good
Zuletzt aktualisiert	25 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

DB:RV7 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1,393	664	N/A	N/A	6
12/31/2025	1,154	517	678	697	9
12/31/2024	989	403	553	565	10
3/31/2024	863	319	424	431	N/A
12/31/2023	829	282	373	389	N/A
9/30/2023	781	254	354	369	N/A
6/30/2023	774	234	293	306	N/A
3/31/2023	705	182	264	279	N/A
12/31/2022	660	202	235	240	N/A
9/30/2022	581	211	238	240	N/A
6/30/2022	487	366	290	292	N/A
3/31/2022	472	435	287	289	N/A
12/31/2021	443	403	298	299	N/A
9/30/2021	463	409	265	268	N/A
6/30/2021	412	229	150	152	N/A
3/31/2021	331	163	116	119	N/A
12/31/2020	268	129	53	55	N/A
9/30/2020	200	22	-24	-22	N/A
6/30/2020	180	-40	-60	-58	N/A
3/31/2020	164	-80	-89	-86	N/A
12/31/2019	196	-72	-89	-85	N/A
9/30/2019	203	-40	-55	-48	N/A
6/30/2019	182	-43	-43	-38	N/A
3/31/2019	178	-51	-36	-32	N/A
12/31/2018	152	-80	-54	-49	N/A
9/30/2018	281	46	91	93	N/A
6/30/2018	319	76	130	132	N/A
3/31/2018	318	68	132	134	N/A
12/31/2017	317	63	N/A	134	N/A
9/30/2017	166	-88	N/A	-35	N/A
6/30/2017	134	-120	N/A	-64	N/A
3/31/2017	134	-116	N/A	-60	N/A
12/31/2016	147	-103	N/A	-50	N/A
9/30/2016	160	-71	N/A	-50	N/A
6/30/2016	149	-67	N/A	-58	N/A
3/31/2016	159	-37	N/A	-36	N/A
12/31/2015	135	-32	N/A	-37	N/A
9/30/2015	113	-42	N/A	-23	N/A
6/30/2015	107	-38	N/A	-19	N/A
3/31/2015	82	-57	N/A	-44	N/A
12/31/2014	75	-68	N/A	-48	N/A
9/30/2014	57	-85	N/A	-62	N/A
6/30/2014	59	-84	N/A	-61	N/A
3/31/2014	55	-91	N/A	-56	N/A
12/31/2013	55	-83	N/A	-49	N/A
9/30/2013	64	-66	N/A	-51	N/A
6/30/2013	53	-67	N/A	-53	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RV7Das prognostizierte Gewinnwachstum (21.7% pro Jahr) liegt über der Sparquote (0.7%).

Ertrag vs. Markt: RV7Die Erträge des Unternehmens (21.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt German (18.6% pro Jahr).

Hohe Wachstumserträge: RV7Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: RV7Die Einnahmen des Unternehmens (15% pro Jahr) werden voraussichtlich schneller wachsen als der Markt German (5.1% pro Jahr).

Hohe Wachstumseinnahmen: RV7Die Einnahmen des Unternehmens (15% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: RV7Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich sehr hoch sein (84.2%).

Halozyme Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Halozyme Therapeutics, Inc. Updates Earnings Guidance for the Full Year 2024

Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for 2024

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Twelve Months Ended December 31, 2023

Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Full Year 2023

Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for the Full Year 2023

Recent updates

Halozyme Therapeutics, Inc. Announces Roche's OCREVUS SC with ENHANZE Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis

Halozyme Therapeutics, Inc. Announces argenx Receives FDA Approval for VYVGART Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy

Independent Director recently sold €928k worth of stock

Halozyme Therapeutics, Inc. Updates Earnings Guidance for the Full Year 2024

Investor sentiment improves as stock rises 19%

First quarter 2024 earnings released: EPS: US$0.60 (vs US$0.29 in 1Q 2023)

Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for 2024

Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors

Halozyme Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Halozyme Therapeutics, Inc., Annual General Meeting, Apr 25, 2024

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: EPS: US$2.13 (vs US$1.48 in FY 2022)

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) announces an Equity Buyback for $750 million worth of its shares.

Halozyme Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Halozyme Announces Argenx Receives Approval in Japan for Vyvdura®? Co-Formulated with Enhanze®? for Generalized Myasthenia Gravis

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Twelve Months Ended December 31, 2023

Halozyme Announces Takeda Receives FDA Approval for Hyqvia® Co-Formulated with Enhanze® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Halozyme Announces Roche Receives European Commission Approval of Tecentriq®? SC with ENHANZE®? Representing the EU's First Subcutaneous PD(L)1 Cancer Immunotherapy for Multiple Cancer Types

Third quarter 2023 earnings released: EPS: US$0.62 (vs US$0.45 in 3Q 2022)

Halozyme Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Halozyme Therapeutics, Inc. Reports Positive Topline Results from the Phase 3 Checkmate-67T Trial Evaluating Subcutaneous (SC) Formulation of Opdivo (Nivolumab) with Enhanze

Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery

Halozyme Therapeutics, Inc Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain

Independent Director recently sold €801k worth of stock

Second quarter 2023 earnings released: EPS: US$0.57 (vs US$0.16 in 2Q 2022)

Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Full Year 2023

Halozyme Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Positive Results Announces from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis

Halozyme Announces argenx Receives FDA Approval for VYVGART Hytrulo With ENHANZE for Subcutaneous Use in Generalized Myasthenia Gravis

First quarter 2023 earnings released: EPS: US$0.29 (vs US$0.44 in 1Q 2022)

Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for the Full Year 2023

Insufficient new directors

Investor sentiment deteriorates as stock falls 16%

Independent Director recently sold €902k worth of stock

Full year 2022 earnings released: EPS: US$1.48 (vs US$2.86 in FY 2021)

Halozyme Therapeutics, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Halozyme Therapeutics Appoints Barbara Duncan to Its Board of Directors

Halozyme Therapeutics, Inc. Provides Revenue Guidance for the Fiscal Year 2023

Independent Director recently sold €1.6m worth of stock

CFO & Director recently sold €259k worth of stock

Third quarter 2022 earnings released: EPS: US$0.45 (vs US$1.53 in 3Q 2021)

Halozyme Therapeutics, Inc. Reiterates Financial Guidance for the Year 2022

Halozyme Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: EPS: US$0.16 (vs US$0.64 in 2Q 2021)

Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Year 2022

Halozyme Therapeutics, Inc. Announces Positive Results from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq with ENHANZE in Advanced Non-Small Cell Lung Cancer

Halozyme Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Investor sentiment improved over the past week

Halozyme Therapeutics, Inc. Announces Commercial Launch of TLANDO, an Oral Treatment for Testosterone Replacement Therapy

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) completed the acquisition of Antares Pharma, Inc. (NasdaqCM:ATRS).

Investor sentiment improved over the past week

Halozyme Therapeutics, Inc. Reiterates Earnings Guidance for the Year 2022

First quarter 2022 earnings released: EPS: US$0.44 (vs US$0.20 in 1Q 2021)

Halozyme Therapeutics, Inc. to Report Q1, 2022 Results on May 10, 2022

Insufficient new directors

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) entered into a definitive agreement to acquire Antares Pharma, Inc. (NasdaqCM:ATRS) for $970 million.

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) entered into a definitive agreement to acquire Antares Pharma, Inc. (NasdaqCM:ATRS) for $970 million.

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Halozyme Therapeutics, Inc. Reiterates Earnings Guidance for the Year 2022

Halozyme Therapeutics, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Halozyme Therapeutics, Inc. Announces Executive Changes

Halozyme Therapeutics, Inc. Announces Change of Chief Financial Officer

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2022

Investor sentiment improved over the past week

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) announces an Equity Buyback for $750 million worth of its shares.

Independent Chairperson of the Board recently sold €1.1m worth of stock

Third quarter 2021 earnings released: EPS US$1.53 (vs US$0.27 in 3Q 2020)

Insufficient new directors